Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Next Previous
X
Search
Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 137173A (Primary) ; GSK 2321138A (Primary)
  • Indications Herpes zoster; Influenza A virus infections
  • Focus Pharmacodynamics; Registrational
  • Acronyms ZOSTER-004
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 26 Sep 2017 Primary endpoint has been met. (FLU Haemagglutination Inhibition (HI) Antibody Titers [ Time Frame: At Day 21 post vaccination ]), according to results published in the Journal of Infectious Diseases.
    • 26 Sep 2017 Primary endpoint has been met. (Adjusted Geometric Mean ELISA Concentrations of Anti-gE Antibodies [ Time Frame: At one month post-dose 2 (Month 3 for GSK1437173A + GSK2321138A group and Month 5 for Control group) ]), according to results published in the Journal of Infectious Diseases.
    • 26 Sep 2017 Primary endpoint has been met. (Vaccine Response for Anti-gE Humoral Immunogenicity [ Time Frame: At one month post-dose 2 (Month 3) ]), according to results published in the Journal of Infectious Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top